Xbrane Biopharma AB Statistics
Xbrane Biopharma AB (7XB0) Stock Statistics & Valuation Metrics
Total Valuation
Xbrane Biopharma AB has a market cap or net worth of EUR 21.24M. The enterprise value is EUR 253.18M.
- Market Cap
- EUR 21.24M
- Enterprise Value
- EUR 253.18M
Share Statistics
Xbrane Biopharma AB has 20,605,349 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 20,605,349
- Owned by Insiders
- ―
- Owned by Institutions
- 0.11%
Financial Efficiency
Xbrane Biopharma AB’s return on equity (ROE) is 0.23 and return on invested capital (ROIC) is -11.66%.
- Return on Equity (ROE)
- 0.23
- Return on Assets (ROA)
- 0.19
- Return on Invested Capital (ROIC)
- -11.66%
- Return on Capital Employed (ROCE)
- -0.12
- Revenue Per Employee
- 5.44M
- Profits Per Employee
- 4.54M
- Employee Count
- 28
- Asset Turnover
- 0.23
- Inventory Turnover
- 0.37
Valuation Ratios
The current PE Ratio of Xbrane Biopharma AB is -6.34. Xbrane Biopharma AB’s PEG ratio is 0.05.
- PE Ratio
- -6.34
- PS Ratio
- 1.09
- PB Ratio
- 0.45
- Price to FCF
- -1.59
- Price to Operating Cash Flow
- -3.07
- PEG Ratio
- 0.05
Income Statement
In the last 12 months, Xbrane Biopharma AB had revenue of 152.35M and earned 127.24M in profits. Earnings per share was 0.08.
- Revenue
- 152.35M
- Gross Profit
- 74.94M
- Operating Income
- -72.14M
- Pretax Income
- -43.93M
- Net Income
- 127.24M
- EBITDA
- -16.50M
- Earnings Per Share (EPS)
- 0.08
Cash Flow
In the last 12 months, operating cash flow was -76.80M and capital expenditures -11.03M, giving a free cash flow of -87.83M billion.
- Operating Cash Flow
- -76.80M
- Free Cash Flow
- -87.83M
- Free Cash Flow per Share
- -4.26
Dividends & Yields
Xbrane Biopharma AB pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -63.00%
- Earnings Yield
- -26.57%
Stock Price Statistics
- Beta
- 1.14
- 52-Week Price Change
- 9.40%
- 50-Day Moving Average
- 0.99
- 200-Day Moving Average
- 0.83
- Relative Strength Index (RSI)
- 46.16
- Average Volume (3m)
- 491
Important Dates
Xbrane Biopharma AB upcoming earnings date is Feb 19, 2027, Before Open (Not Confirmed).
- Last Earnings Date
- Oct 30, 2026
- Next Earnings Date
- Feb 19, 2027
- Ex-Dividend Date
- ―
Financial Position
Xbrane Biopharma AB as a current ratio of 7.12, with Debt / Equity ratio of 10.40%
- Current Ratio
- 7.12
- Quick Ratio
- 3.43
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.71
- Interest Coverage Ratio
- -4.40
Taxes
In the past 12 months, Xbrane Biopharma AB has paid 2.23M in taxes.
- Income Tax
- 2.23M
- Effective Tax Rate
- -0.05
Enterprise Valuation
Xbrane Biopharma AB EV to EBITDA ratio is -3.53, with an EV/FCF ratio of -1.89.
- EV to Sales
- 1.30
- EV to EBITDA
- -3.53
- EV to Free Cash Flow
- -1.89
- EV to Operating Cash Flow
- -2.16
Balance Sheet
Xbrane Biopharma AB has EUR 37.41M in cash and marketable securities with EUR 63.93M in debt, giving a net cash position of -EUR 26.52M billion.
- Cash & Marketable Securities
- EUR 37.41M
- Total Debt
- EUR 63.93M
- Net Cash
- -EUR 26.52M
- Net Cash Per Share
- -EUR 1.29
- Tangible Book Value Per Share
- EUR 9.68
Margins
Gross margin is 6.91%, with operating margin of -45.28%, and net profit margin of -48.99%.
- Gross Margin
- 6.91%
- Operating Margin
- -45.28%
- Pretax Margin
- -48.27%
- Net Profit Margin
- -48.99%
- EBITDA Margin
- -36.70%
- EBIT Margin
- -45.28%
Analyst Forecast
The average price target for Xbrane Biopharma AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -37.13%
- EPS Growth Forecast
- -119.85%
